• In late June 2026, Edwards Lifesciences announced new clinical data across its aortic, mitral and tricuspid portfolios at New York Valves 2026, while also being reclassified into several Russell midcap and defensive value indexes following its removal from the Russell Top 200 group.
• The fresh evidence around the PROGRESS, PARTNER 3, EARLY TAVR, PASCAL and ENCIRCLE studies highlights how Edwards is aiming to broaden treatment options for complex structural heart disease patients beyond current guideline-recommended pathways.
• We’ll now examine how these new data on Edwards’ SAPIEN platform and broader valve portfolio could influence its existing investment narrative.

Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.

Edwards Lifesciences Investment Narrative Recap

To own Edwards Lifesciences, you need to be confident that its transcatheter valve portfolio can keep attracting patients and clinicians, even as tariffs, competition and acquisition-related costs pressure margins. The latest New York Valves data and Russell index moves reinforce Edwards’ position in structural heart therapies, but do not materially change the near term focus on execution around early TAVR indications and managing EPS dilution from JenaValve and higher operating expenses.

Among the recent announcements, the new data from the EARLY TAVR trial stand out as most relevant, because they directly relate to Edwards’ push into treating moderate or earlier-stage aortic stenosis. These results sit alongside PROGRESS and PARTNER 3 durability findings and support the clinical case that underpins expectations for an expanded TAVR treatment pool, which many investors see as a key offset to rising costs and international competitive pressure over time.

Yet, while the clinical story is compelling, investors should also be aware of how prolonged regulatory timelines for early TAVR indications could...

Edwards Lifesciences’ narrative projects $8.3 billion revenue and $2.2 billion earnings by 2029. This requires 9.6% yearly revenue growth and roughly a $1.1 billion earnings increase from $1.1 billion today.

Uncover how Edwards Lifesciences' forecasts yield a $96.92 fair value, a 3% upside to its current price.

Exploring Other Perspectives

Two fair value estimates from the Simply Wall St Community cluster tightly around US$96.84 to US$96.92, showing how differently individual investors can think yet converge numerically. You can weigh those views against the early TAVR indication catalyst, which many see as central to Edwards’ longer term performance and worth comparing with several alternative scenarios.

Explore 2 other fair value estimates on Edwards Lifesciences - why the stock might be worth just $96.84!

Decide For Yourself

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Edwards Lifesciences research is our analysis highlighting 2 key rewards and 3 important warning signs that could impact your investment decision.
• Our free Edwards Lifesciences research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Edwards Lifesciences' overall financial health at a glance.

Want Some Alternatives?

Right now could be the best entry point. These picks are fresh from our daily scans. Don't delay:

• The future of work is here. Discover the 29 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
• Find 44 companies with promising cash flow potential yet trading below their fair value.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.